Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Hepatology International
Published in: Hepatology International 2/2017

01-03-2017 | Review Article

Sofosbuvir/velpatasvir: a pangenotypic drug to simplify HCV therapy

Authors: Rebecca Lee, Shyam Kottilil, Eleanor Wilson

Published in: Hepatology International | Issue 2/2017

Login to get access

Abstract

Treatment for chronic hepatitis C virus (HCV) has evolved rapidly from an interferon based regimen of modest efficacy with significant adverse events to a well-tolerated, highly effective all-oral directly acting antiviral (DAA) therapy. Although significant improvement in sustained virologic responses (SVR) has been reported with new DAAs for genotypes 1 and 4, effective treatments for genotype 3 have been lacking, and a single pill that can yield high SVR rates against HCV genotypes 1–6 has not been available until now. Sofosbuvir (a pangenotypic NS5B inhibitor) and velpatasvir (a pangenotypic NS5A inhibitor) were recently approved in a fixed-dose combination pill. The availability of this pangenotypic pill holds promise for providing highly effective treatment with minimal laboratory testing for chronic HCV worldwide.
Literature
1.
Organization WH. Guidelines for the screening, care and treatment of persons with chronic hepatitis c infection. World Health Organization, Updated Recommendations. 2016; pp. 19–20
2.
Poordad F, Dieterich D. Treating hepatitis C: current standard of care and emerging direct-acting antiviral agents. J Viral Hepat 2012;19:449–464CrossRef
3.
Narayanan S, Townsend K, Macharia T. Favorable adverse event profile of sofosbuvir/ribavirin compared to boceprevir/interferon/ribavirin for treatment of hepatitis C. Hep Intl 2014;5:560–566CrossRef
4.
5.
Backus LI, Belperio PS, Shahoumian TA. Real-world effectiveness of ledispavir/sofosbuvir in 4,365 treatment-naive genotype 1 hepatits C-infected patients. Hepatology 2016;64:405–414CrossRefPubMed
6.
Kumari R, Nguyen M. Fixed-dose combination of sofosbuvir and ledipasvir for the treatment of chronic hepatitis C genotype 1. Expert Opin Pharmacother 2015;16:739–748CrossRefPubMed
7.
Jazwinski AB, Muir AJ. Direct-acting antiviral medications for chronic hepatitis C virus infection. Gastroenterol Hepatol 2011;7:154–162
8.
Blackard J, Sherman, K. Hepatitis C virus confection and superinfection. Journal of Infectious Diseases 2007;195:519–524CrossRefPubMed
9.
Smith DB, Bukh J, Kuiken C. Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment web resource. Hepatology 2014;59:318–327CrossRefPubMed
10.
Messina JP, Humphreys I, Flaxman A. Global distribution and prevalence of hepatitis C virus genotypes. Hepatology. 2015;61:77–87CrossRefPubMed
11.
Lawitz EJ. Clinical resistance to velpatasvir (GS-5816), a novel pan-genotypic inhibitor of the hepatitis C virus NS5A protein. Antimicrobial Agents and Chemotherapy 2016;60:5368–5378CrossRefPubMedPubMedCentral
12.
Kohli A, Kapoor R, Sims Z. Ledispavir and sofosbuvir for hepatatis C genotype 4: a proof-of concept, single-centre, open-label phase 2a cohort study. Lancet Infect Dis 2015;15:1049–1054CrossRefPubMedPubMedCentral
13.
14.
Foster GR, Afdhal N, Roberts SK. Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection. N Engl J Med 2015;373:2608–2617CrossRefPubMed
15.
Pham ST, Bull RA. Frequent multiple hepatitis C virus infections among injection drug users in a prison setting. Hepatology 2010;52:1564–1573CrossRefPubMed
16.
Kattakuzhy S, Levy R, Kottilil S. Sofosbuvir for treatment of chronic hepatitis C. Hep Intl 2015;9:161–173CrossRef
17.
18.
Hussaini T. Paritaprevir/ritonavir-ombitasvir and dasabuvir, the 3D regimen for the treatment of chronic hepatitis C virus infection: a concise review. Hepat Med Evid Res 2016;8:61–68CrossRef
19.
Everson GT, Towner WJ, Davis MN. Sofosbuvir with velpatasvir in treatment-naive noncirrhotic patients with genotype 1 to 6 hepatitis C virus infection. Ann Intern Med 2015;163:818–826CrossRefPubMed
20.
Pianko S, Flamm SL, Shiffman ML. Sofosbuvir plus velpatasvir combination therapy for treatment-experienced patients with genotype 1 or 3 hepatitis C virus infection. Ann Intern Med 2015;163:809–817CrossRefPubMed
21.
Feld JJ, Jacobson IM, Hezode C. Sofosbuvir and velpatasvir for HCV genotype 1,2,4,5, and 6 infection. N Engl J Med 2015;373:2599–2607CrossRefPubMed
22.
Nguyen MH, Keeffe EB. Prevalence and treatment of hepatitis C virus genotypes 4, 5, and 6. Clin Gastroenterol Hepatol 2005: 3(10 Suppl 2):S97–S101
23.
Takana Y, Nishida N, Sugiyama M. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 2009;41:1105–1109CrossRef
24.
Curry MP, JO’Leary JG, Bzowej N. Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis. N Engl J Med 2015;373:2618–2628CrossRefPubMed
25.
26.
Wyles, D, Brau, N, Kottilil, S. Sofosbuvir/Belpatasvir Single-Tablet Regimen for 12 Weeks in Patients Co-Infected with HCV and HIV-1: the Phase 3 ASTRAL-5 Study. In The International Liver Congress for the European Association for the Study of the Liver. Barcelona, Spain; 2016
27.
Gane EJ, Shiffman ML, Etzkorn K. Sofosbuvir/Velpatasvir in Combination with Ribavirin for 24 Weeks is Effective Retreatment for Patients who Failed Prior NS5A-Containing DAA Regimens: Results of the Retreatment Study. In The International Liver Congress European Association for the Study of the Liver. Barcelona, Spain; 2016
28.
Lontok E, Harrington P, Howe A. Hepatitis C virus drug resistance-associated substitutions: state of the art summary. Hepatology 2015;62:1623–1632CrossRefPubMed
29.
Wilson E, Kattakuzhy S, Sidharthan S. Successful retreatment of chronic HCV genotype-1 infection with ledispavir and sofosuvir after initial short course therapy with direct-acting antiviral regimens. Clin Infect Dis 2016;62:280–288CrossRefPubMed
30.
Wilson EM, Rosenthal ES, Kattakuzhy S. Clinical laboratory testing in the era of direct acting antiviral therapies for hepatitis C. Clin Microbiol Rev 2016;30:23–42CrossRefPubMed
31.
Cheng G, Tian Y, Doehle B, Peng B, Corsa A, Lee YJ, Gong R, et al. In vitro antiviral activity and resistance profile characterization of the hepatitis C virus NS5A inhibitor ledipasvir. Antimicrob Agents Chemother 2016;60:1847–1853CrossRefPubMedPubMedCentral
32.
Lontok E, Harrington P, Howe A, Kieffer T, Lennerstrand J, Lenz O, McPhee F, et al. Hepatitis C virus drug resistance-associated substitutions: state of the art summary. Hepatology 2015;62:1623–1632CrossRefPubMed
33.
Lawitz EJ, Dvory-Sobol H, Doehle B, Worth A, McNally J, Brainard DM, Link JO, et al. Clinical resistance to velpatasvir (GS-5816), a novel pan-genotypic inhibitor of the hepatitis C virus NS5A protein. Antimicrob Agents Chemother 2016;60(9):5368–5378CrossRefPubMedPubMedCentral
34.
Rosenthal ES, Kottilil S, Polis MA. Sofosbuvir and ledispavir for HIV/HCV co-infected patients. Expert Opin Pharmacother 2016;17:743–749CrossRefPubMed
35.
Lawitz E, Poordad F, Gutierrez J. SVR12 results from the Phase II, open-label IMPACT study of simeprevir (SMV) in combination with daclatasvir (DCV) and sofosbuvir (SOF) in treatment-naïve and -experienced patients with chronic HCV genotype 1/4 infection and decompensated liver disease In 66th Annual Meeting of the American Association for the Study of Liver Diseases. Boston, MA; 2015
36.
Omata M, Kanda T, Wei L. APASL consensus statements and recommendations for hepatitis C prevention, epidemiology, and laboratory testing. Hepatol Int 2016;10:681–701CrossRefPubMedPubMedCentral
37.
Lau G, Benhamou Y, Chen G. Efficacy and safety of 3-week response-guided triple direct-acting antiviral therapy for chronic hepatitis C infection: a phase 2, open-label, proof-of-concept study. Lancet Gastroenterol Hepatol 2016;1:97–104CrossRefPubMed
38.
Ji D, Chen GF, Wang C. Twelve-week ribavirin-free direct-acting antivirals for treatmentexperienced Chinese with HCV genotype 1b infection including cirrhotic patients. Hepatol Int 2016;10:789–798CrossRefPubMed
39.
Kohli A, Osinusi A, Sims Z. Virological response after 6 week triple-drug regimens for hepatatis C: a proof-of-concept 2A cohort study. Lancet 2015;385:1107–1113CrossRefPubMedPubMedCentral
40.
Kohli A, Sarah K, Sidharthan S. Four-week direct-acting antiviral regimens in noncirrhotic patients with hepatitis C Virus genotype 1 infection. Ann Intern Med 2015;163:899–907CrossRefPubMed
Metadata
Title
Sofosbuvir/velpatasvir: a pangenotypic drug to simplify HCV therapy
Authors
Rebecca Lee
Shyam Kottilil
Eleanor Wilson
Publication date
01-03-2017
Publisher
Springer India
Published in
Hepatology International / Issue 2/2017
Print ISSN: 1936-0533
Electronic ISSN: 1936-0541
DOI
https://doi.org/10.1007/s12072-016-9776-8

Other articles of this Issue 2/2017

Hepatology International 2/2017 Go to the issue

Review Article

Virus-induced hepatocellular carcinoma with special emphasis on HBV

Original Article

Clinical validity of Metroticket calculator in transplant patients undergoing prior chemoembolization for hepatocellular carcinoma

Original Article

Efficacy and safety of daclatasvir plus pegylated-interferon alfa 2a and ribavirin in previously untreated HCV subjects coinfected with HIV and HCV genotype-1: a Phase III, open-label study

Editorial

Secondary prophylaxis for variceal bleeding: carvedilol vs. propranolol

Original Article

HATT: a phase IV, single-arm, open-label study of sorafenib in Taiwanese patients with advanced hepatocellular carcinoma

Point of View

Living donor liver transplant (LDLT) is the way forward in Asia

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits